Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29


Characterization of ABBV-221, a Tumor-Selective EGFR Targeting Antibody Drug Conjugate.

Phillips AC, Boghaert ER, Vaidya KS, Falls HD, Mitten MJ, DeVries PJ, Benatuil L, Hsieh CM, Meulbroek JA, Panchal SC, Buchanan FG, Durbin KR, Voorbach MJ, Reuter DR, Mudd SR, Loberg LI, Ralston SL, Cao D, Gan HK, Scott AM, Reilly EB.

Mol Cancer Ther. 2018 Feb 26. pii: molcanther.0710.2017. doi: 10.1158/1535-7163.MCT-17-0710. [Epub ahead of print]


The Volume of Three-Dimensional Cultures of Cancer Cells InVitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors.

Boghaert ER, Lu X, Hessler PE, McGonigal TP, Oleksijew A, Mitten MJ, Foster-Duke K, Hickson JA, Santo VE, Brito C, Uziel T, Vaidya KS.

Neoplasia. 2017 Sep;19(9):695-706. doi: 10.1016/j.neo.2017.06.004. Epub 2017 Aug 5.


A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.

Vaidya KS, Oleksijew A, Tucker LA, Pappano WN, Anderson MG, Grinnell CM, Zhang Q, Heighton SJ, Mitten MJ, Mishra S, Palma JP, Wang J, Reilly EB, Boghaert ER.

Pharmacology. 2017;100(5-6):229-242. doi: 10.1159/000478663. Epub 2017 Jul 26.


ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.

Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP, Naumovski L, Reilly EB.

Clin Cancer Res. 2017 Feb 15;23(4):992-1000. doi: 10.1158/1078-0432.CCR-16-1568. Epub 2016 Aug 29.


Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.

Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya KS, Oleksijew A, Boghaert E, Song M, Sokolova I, Pestova E, Anderson M, Pappano WN, Ansell P, Bhathena A, Naumovski L, Corvaia N, Reilly EB.

BMC Cancer. 2016 Feb 16;16:105. doi: 10.1186/s12885-016-2138-z.


ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.

Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG, McKay LM, Goodwin NC, Reilly EB.

Mol Cancer Ther. 2016 Apr;15(4):661-9. doi: 10.1158/1535-7163.MCT-15-0901. Epub 2016 Feb 4.


Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, Belmont LD, Nimmer P, Xiao Y, Ma XM, Lowes KN, Kovar P, Chen J, Jin S, Smith M, Xue J, Zhang H, Oleksijew A, Magoc TJ, Vaidya KS, Albert DH, Tarrant JM, La N, Wang L, Tao ZF, Wendt MD, Sampath D, Rosenberg SH, Tse C, Huang DC, Fairbrother WJ, Elmore SW, Souers AJ.

Sci Transl Med. 2015 Mar 18;7(279):279ra40. doi: 10.1126/scitranslmed.aaa4642.


Metastasis suppressor KISS1 seems to reverse the Warburg effect by enhancing mitochondrial biogenesis.

Liu W, Beck BH, Vaidya KS, Nash KT, Feeley KP, Ballinger SW, Pounds KM, Denning WL, Diers AR, Landar A, Dhar A, Iwakuma T, Welch DR.

Cancer Res. 2014 Feb 1;74(3):954-63. doi: 10.1158/0008-5472.CAN-13-1183. Epub 2013 Dec 18.


Subsets of ATP-sensitive potassium channel (KATP) inhibitors increase gap junctional intercellular communication in metastatic cancer cell lines independent of SUR expression.

Bodenstine TM, Vaidya KS, Ismail A, Beck BH, Diers AR, Edmonds MD, Kirsammer GT, Landar A, Welch DR.

FEBS Lett. 2012 Jan 2;586(1):27-31. doi: 10.1016/j.febslet.2011.11.017. Epub 2011 Nov 24.


Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERĪ± negative breast cancer cell lines.

Kwon YJ, Hurst DR, Steg AD, Yuan K, Vaidya KS, Welch DR, Frost AR.

Clin Exp Metastasis. 2011 Jun;28(5):437-49. doi: 10.1007/s10585-011-9382-z. Epub 2011 Mar 27.


Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition.

Bodenstine TM, Vaidya KS, Ismail A, Beck BH, Cook LM, Diers AR, Landar A, Welch DR.

Cancer Res. 2010 Dec 1;70(23):10002-11. doi: 10.1158/0008-5472.CAN-10-2606. Epub 2010 Nov 23.


Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression.

Edmonds MD, Hurst DR, Vaidya KS, Stafford LJ, Chen D, Welch DR.

Int J Cancer. 2009 Oct 15;125(8):1778-85. doi: 10.1002/ijc.24616.


Expression of the Breast Cancer Metastasis Suppressor 1 (BRMS1) maintains in vitro chemosensitivity of breast cancer cells.

Vaidya KS, Sanchez JJ, Kim EL, Welch DR.

Cancer Lett. 2009 Aug 18;281(1):100-7. doi: 10.1016/j.canlet.2009.02.035.


Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone.

Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR.

Oncol Rep. 2009 Mar;21(3):761-7.


Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis.

Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR.

Cancer Res. 2009 Feb 15;69(4):1279-83. doi: 10.1158/0008-5472.CAN-08-3559. Epub 2009 Feb 3.


Over-expression of the BRMS1 family member SUDS3 does not suppress metastasis of human cancer cells.

Silveira AC, Hurst DR, Vaidya KS, Ayer DE, Welch DR.

Cancer Lett. 2009 Apr 8;276(1):32-7. doi: 10.1016/j.canlet.2008.10.024. Epub 2008 Dec 13.


Metastasis Research Society-American Association For Cancer Research Joint Conference on Metastasis.

Welch DR, Cooper CR, Hurst DR, Lynch CC, Martin MD, Vaidya KS, VanSaun MN, Mastro AM.

Cancer Res. 2008 Dec 1;68(23):9578-82. doi: 10.1158/0008-5472.CAN-08-3360. No abstract available.


Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling.

Vaidya KS, Harihar S, Phadke PA, Stafford LJ, Hurst DR, Hicks DG, Casey G, DeWald DB, Welch DR.

J Biol Chem. 2008 Oct 17;283(42):28354-60. doi: 10.1074/jbc.M710068200. Epub 2008 Jul 29.


BRMS1 suppresses breast cancer metastasis in multiple experimental models of metastasis by reducing solitary cell survival and inhibiting growth initiation.

Hedley BD, Vaidya KS, Phadke P, MacKenzie L, Dales DW, Postenka CO, MacDonald IC, Chambers AF.

Clin Exp Metastasis. 2008;25(7):727-40. doi: 10.1007/s10585-008-9184-0. Epub 2008 Jun 10.


2-Aminomethyl piperidines as novel urotensin-II receptor antagonists.

Jin J, Wang Y, Wang F, Shi D, Erhard KF, Wu Z, Guida BF, Lawrence SK, Behm DJ, Disa J, Vaidya KS, Evans C, McMillan LJ, Rivero RA, Neeb MJ, Douglas SA.

Bioorg Med Chem Lett. 2008 May 1;18(9):2860-4. doi: 10.1016/j.bmcl.2008.03.078. Epub 2008 Apr 8.


Metastasis suppressors genes in cancer.

Stafford LJ, Vaidya KS, Welch DR.

Int J Biochem Cell Biol. 2008;40(5):874-91. doi: 10.1016/j.biocel.2007.12.016. Epub 2008 Jan 15. Review.


BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process.

Phadke PA, Vaidya KS, Nash KT, Hurst DR, Welch DR.

Am J Pathol. 2008 Mar;172(3):809-17. doi: 10.2353/ajpath.2008.070772. Epub 2008 Feb 14.


Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells.

Hurst DR, Xie Y, Vaidya KS, Mehta A, Moore BP, Accavitti-Loper MA, Samant RS, Saxena R, Silveira AC, Welch DR.

J Biol Chem. 2008 Mar 21;283(12):7438-44. doi: 10.1074/jbc.M709446200. Epub 2008 Jan 22.


Metastasis suppressors and their roles in breast carcinoma.

Vaidya KS, Welch DR.

J Mammary Gland Biol Neoplasia. 2007 Sep;12(2-3):175-90. Review.


Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy.

Nash KT, Phadke PA, Navenot JM, Hurst DR, Accavitti-Loper MA, Sztul E, Vaidya KS, Frost AR, Kappes JC, Peiper SC, Welch DR.

J Natl Cancer Inst. 2007 Feb 21;99(4):309-21. Erratum in: J Natl Cancer Inst. 2007 Jul 20;99(12):977.


Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action.

Sabbisetti VS, Chirugupati S, Thomas S, Vaidya KS, Reardon D, Chiriva-Internati M, Iczkowski KA, Shah GV.

Int J Cancer. 2005 Nov 20;117(4):551-60.


1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).

Heerding DA, Chan G, DeWolf WE, Fosberry AP, Janson CA, Jaworski DD, McManus E, Miller WH, Moore TD, Payne DJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Smith W, Takata DT, Vaidya KS, Yuan CC, Huffman WF.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2061-5.


Automated assay optimization with integrated statistics and smart robotics.

Taylor PB, Stewart FP, Dunnington DJ, Quinn ST, Schulz CK, Vaidya KS, Kurali E, Lane TR, Xiong WC, Sherrill TP, Snider JS, Terpstra ND, Hertzberg RP.

J Biomol Screen. 2000 Aug;5(4):213-26.


Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality.

Lee D, Long SA, Adams JL, Chan G, Vaidya KS, Francis TA, Kikly K, Winkler JD, Sung CM, Debouck C, Richardson S, Levy MA, DeWolf WE Jr, Keller PM, Tomaszek T, Head MS, Ryan MD, Haltiwanger RC, Liang PH, Janson CA, McDevitt PJ, Johanson K, Concha NO, Chan W, Abdel-Meguid SS, Badger AM, Lark MW, Nadeau DP, Suva LJ, Gowen M, Nuttall ME.

J Biol Chem. 2000 May 26;275(21):16007-14.

Supplemental Content

Loading ...
Support Center